Taltz
(Ixekizumab)ApprovedMonoclonal antibody
Eli LillyIxekizumab is used to treat inflammatory conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis by reducing the immune system's inflammatory response that causes joint pain, swelling, and skin problems.[2] Taltz is currently approved and in use across 25 indications[4].[1]
Taltz is one of 468 monoclonal antibody programs targeting Pyoderma Gangrenosum. It is currently in Approved.
25
Indications
56
Total Trials
13
Active Trials
467
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 25 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Taltz
Eli LillyApproved
Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Psoriasis20 trials
Show 17 more trials
Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06811558·100 enrolled
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
Active, not recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT06945107·308 enrolled
Psoriatic Arthritis8 trials
Show 5 more trials
Arthritis5 trials
ART3 trials
18 more indications
Uveitis1 trial
Juvenile Idiopathic Arthritis1 trial
Ankylosing Spondylitis1 trial
Overweight1 trial
Pyoderma Gangrenosum1 trial
Generalized Pustular Psoriasis1 trial
Tics1 trial
Immune Response1 trial
Depressive Symptoms1 trial
Guttate Psoriasis1 trial
Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT06374979·50 enrolled
Regulatory
FDA Approval Timeline[5]
Mar 22, 2016
TALTZ
BLA BLA125521
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Taltz drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ixekizumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]